Interesting AME Put And Call Options For September 18th

Stock Options Channel presents trade ideas for AMETEK (AME) at a spot price of $214.12: a sell-to-open $210 put (bid $10.90) would set an effective purchase basis of $199.10 and is ~2% OTM with a 61% probability of expiring worthless, yielding 5.19% (7.70% annualized) if it does. On the call side, selling a $220 covered call (bid $13.50) against current shares would generate a 9.05% total return if called at the September 18 expiration, with a 48% chance of expiring worthless and a 6.30% YieldBoost (9.36% annualized). Implied volatility for both contracts is about 24% versus a trailing 12‑month realized volatility of 23%; the piece is effectively a tactical options-income idea rather than company fundamental news.

Analysis

Market structure: Short-dated income strategies (options sellers) are the clear beneficiaries—selling the Sep 18 AME $210 put yields a 5.19% cash-on-collateral return (7.7% annualized) and the $220 covered call yields ~9.05% to expiry. Equity holders face capped upside or assignment risk; dealers and market makers who delta-hedge these flows can create 1–3% directional share moves into expiry windows. Modest IV (24%) aligned with realized vol (23%) signals limited risk premium; demand is for yield not directional conviction.

Risk assessment: Tail risks are asymmetric: a >10% gap down (earnings miss, industrial capex shock) would convert collected premium into realized loss quickly, especially for put sellers assigned at $210 (effective $199.10). Time horizons matter—days: gamma/hedge flows around Sep 18; weeks: IV reversion to >30% would widen bid/ask and hurt sellers; quarters: fundamental order-book deterioration could compress multiple. Hidden dependencies include counterparty margining and collateral needs—one contract = $21,000 notional exposure.

Trade implications: Direct play—sell-to-open AME Sep18 $210 puts sized to 1–2% portfolio equity, with $21k collateral per contract; target entry now, roll or close if AME < $195 or IV > 30%. Buy-write alternative—establish 1–1.5% long AME and sell Sep18 $220 calls (collect $13.50) for ~9% gross return to expiry; exit/roll above $235 or re-evaluate after earnings. Relative value—express confidence via long AME / short EMR 1:1 (0.5–1% portfolio) to isolate company-specific strength.

Contrarian angles: The market is underpricing tail-risk because IV≈realized; a sudden macro slowdown would flip these “income” plays into loss-makers rapidly—history (Q4 2018) shows sell-write strategies can lose >10% fast. The consensus view underestimates opportunity cost if AME rallies >8% (calls cap upside); consider asymmetric structures (put-sell + OTM protective put) rather than naked premium-selling. Watch Sep 18 earnings/guidance and manufacturing PMI in next 30 days as catalysts that could make this trade either cheap or toxic.

Key Decisions for Investors

• Sell-to-open AME Sep18 2026 $210 puts up to a net exposure equal to 1–2% of portfolio (e.g., 3 contracts per $5M AUM), collect $10.90 ($1,090/contract), reserve $21,000 collateral per contract; hard stop/roll if AME < $195 or IV > 30%.
• Establish a 1–1.5% long position in AME (buy shares) and sell Sep18 2026 $220 calls (collect $13.50) as a buy-write to target ~9.05% return to expiry; roll out/away if shares trade >$235 or close before earnings if guidance weakens >5%.
• Implement a pair trade: long AME / short EMR (Emerson, EMR) 1:1 sized 0.5–1% portfolio to express stock-specific outperformance; cut pair if AME underperforms EMR by >5% over 10 trading days or if AME order backlog guidance misses by >8%.
• If assigned on puts or holding shares post-assignment, buy protective Sep18 2026 $195 puts (or equivalent collar) to cap downside; exit protection if AME recovers above $210 or after two consecutive positive monthly PMI prints.